AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer - MedCity News
The FDA has approved Datroway, a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, as a first-line treatment for metastatic triple-negative breast cancer (TNBC), showing significant improvements in progression-free and overall survival compared to chemotherapy. This new therapy provides an alternative for TNBC patients who are not candidates for immunotherapy, positioning Datroway ahead of Gilead's Trodelvy in treatment options for this challenging cancer type.
Daiichi Sankyo and AstraZeneca's newly FDA-approved drug, Datroway, represents a significant advancement in the treatment of metastatic triple-negative breast cancer (TNBC) for patients ineligible for immunotherapy, offering a 43% reduced risk of disease progression or death compared to chemotherapy. For professionals tracking advancements in precision medicine and antibody drug conjugates (ADCs), this approval underscores the potential competitive edge of Datroway over Gilead's Trodelvy, making it a compelling point of interest for investment or strategic partnerships in the biotech and pharmaceutical sectors.